Pacira Biosciences, Stock Revenue
| PCRX Stock | USD 17.55 0.17 0.98% |
Pacira BioSciences, fundamentals help investors to digest information that contributes to Pacira BioSciences,'s financial success or failures. It also enables traders to predict the movement of Pacira Stock. The fundamental analysis module provides a way to measure Pacira BioSciences,'s intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pacira BioSciences, stock.
Pacira |
Pacira BioSciences, Company Revenue Analysis
Pacira BioSciences,'s Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Pacira BioSciences, Revenue | 674.98 M |
Most of Pacira BioSciences,'s fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pacira BioSciences, is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Based on the latest financial disclosure, Pacira BioSciences, reported 674.98 M of revenue. This is 91.15% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The revenue for all United States stocks is 92.85% higher than that of the company.
Pacira Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pacira BioSciences,'s direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pacira BioSciences, could also be used in its relative valuation, which is a method of valuing Pacira BioSciences, by comparing valuation metrics of similar companies.Pacira BioSciences, is currently under evaluation in revenue category among its peers.
Pacira Fundamentals
| Return On Equity | -0.11 | ||||
| Return On Asset | 0.0417 | ||||
| Profit Margin | (0.13) % | ||||
| Operating Margin | 0.13 % | ||||
| Current Valuation | 1 B | ||||
| Shares Outstanding | 46.17 M | ||||
| Shares Owned By Insiders | 2.10 % | ||||
| Shares Owned By Institutions | 97.90 % | ||||
| Number Of Shares Shorted | 5.46 M | ||||
| Price To Earning | 14.34 X | ||||
| Price To Book | 1.08 X | ||||
| Price To Sales | 1.17 X | ||||
| Revenue | 674.98 M | ||||
| Gross Profit | 393.23 M | ||||
| EBITDA | 162.9 M | ||||
| Net Income | 41.95 M | ||||
| Cash And Equivalents | 316.39 M | ||||
| Cash Per Share | 6.90 X | ||||
| Total Debt | 586.04 M | ||||
| Debt To Equity | 1.10 % | ||||
| Current Ratio | 3.95 X | ||||
| Book Value Per Share | 16.24 X | ||||
| Cash Flow From Operations | 154.65 M | ||||
| Short Ratio | 9.34 X | ||||
| Earnings Per Share | (1.98) X | ||||
| Price To Earnings To Growth | (3.83) X | ||||
| Target Price | 18.0 | ||||
| Number Of Employees | 711 | ||||
| Beta | 0.82 | ||||
| Market Capitalization | 810.34 M | ||||
| Total Asset | 1.57 B | ||||
| Retained Earnings | (106.8 M) | ||||
| Working Capital | 412.61 M | ||||
| Current Asset | 252.58 M | ||||
| Current Liabilities | 149.79 M | ||||
| Net Asset | 1.57 B |
About Pacira BioSciences, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pacira BioSciences,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pacira BioSciences, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pacira BioSciences, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Pacira Stock Analysis
When running Pacira BioSciences,'s price analysis, check to measure Pacira BioSciences,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacira BioSciences, is operating at the current time. Most of Pacira BioSciences,'s value examination focuses on studying past and present price action to predict the probability of Pacira BioSciences,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pacira BioSciences,'s price. Additionally, you may evaluate how the addition of Pacira BioSciences, to your portfolios can decrease your overall portfolio volatility.